Compare JMIA & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JMIA | ANL |
|---|---|---|
| Founded | 2012 | 2004 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 899.2M | 731.6M |
| IPO Year | 2018 | 2022 |
| Metric | JMIA | ANL |
|---|---|---|
| Price | $7.01 | $11.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $16.75 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 2.8M | 151.7K |
| Earning Date | 05-07-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $22.18 | $36.02 |
| Revenue Next Year | $23.26 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.02 | $0.88 |
| 52 Week High | $14.72 | $17.25 |
| Indicator | JMIA | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 45.82 | 46.75 |
| Support Level | $6.51 | $6.92 |
| Resistance Level | $9.49 | $12.09 |
| Average True Range (ATR) | 0.37 | 1.33 |
| MACD | -0.01 | -0.13 |
| Stochastic Oscillator | 25.14 | 27.74 |
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace that connects sellers with consumers. The logistics services of the company enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. The company generates revenue from first-party sales, third-party sales, marketing and advertising, and the provision of other services. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates majority of its revenue from the West Africa segment.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.